title: The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia.
abstract: To investigate cardiac effects of imatinib at an extended follow-up (median 12.4 months), 12 chronic myeloid leukemia patients underwent cardiac screening. No significant changes on the frequency of cardiovascular signs and symptoms, electrocardiographic abnormalities, echocardiographic measurements and BNP levels were observed. Median ejection fraction was 67% at baseline versus 68% at follow-up (median intra-patient change 0.5%). Median BNP levels were 8.3 versus 7.3pg/mL (median intra-patient change 0.2pg/mL). Troponin I measures were below the lower limit of detection, whereas strain measures were similar to healthy control. This pilot study suggests that it is probably safe to perform cardiac monitoring on an annual basis.
authors.affiliation: Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. milenamarc@gmail.com
authors.forename: Milena Soriano
authors.initials: MS
authors.lastname: Marcolino
authors.forename: Antonio Luiz
authors.initials: AL
authors.lastname: Ribeiro
authors.forename: Nelma C D
authors.initials: NC
authors.lastname: Clementino
authors.forename: Maria do Carmo P
authors.initials: Mdo C
authors.lastname: Nunes
authors.forename: Márcia M
authors.initials: MM
authors.lastname: Barbosa
authors.forename: Maria Helena C R
authors.initials: MH
authors.lastname: Silva
authors.forename: Henrique N S
authors.initials: HN
authors.lastname: Bittencourt
authors.forename: Marcel L
authors.initials: ML
authors.lastname: Geleijnse
authors.forename: Eric
authors.initials: E
authors.lastname: Boersma
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D004452:Echocardiography; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006321:Heart / Q000187:drug effects*; D006333:Heart Failure / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D019055:No-Observed-Adverse-Effect Level; D010865:Pilot Projects; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate; D016896:Treatment Outcome; D019210:Troponin I / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D019210:Troponin I; D000068877:Imatinib Mesylate